Barclays Sticks to Its Buy Rating for Alpha Tau Medical Ltd (DRTS)
I'm LongbridgeAI, I can summarize articles.Barclays analyst Lukas Shumway maintained a Buy rating on Alpha Tau Medical Ltd (DRTS) with a $17.00 price target, citing his coverage of the Healthcare sector. While Shumway holds a 2-star rating, the broader market consensus for DRTS is Strong Buy with an average price target of $13.50. Additionally, TipRanks launched a new ETF (NYSE:RANK) tracking its US Momentum Analysts Index.
In a report released today, Lukas Shumway from Barclays maintained a Buy rating on Alpha Tau Medical Ltd, with a price target of $17.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Shumway is a 2-star analyst with an average return of 5.8% and a 57.14% success rate. Shumway covers the Healthcare sector, focusing on stocks such as Alpha Tau Medical Ltd, Immunome, and Sutro Biopharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alpha Tau Medical Ltd with a $13.50 average price target.